Abstract
In North America and Europe, serogroup B causes most cases of meningococcal disease in infants.1–3 The first serogroup B meningococcal vaccine, 4CMenB (Bexsero; GlaxoSmithKline, Rixensart, Belgium), was authorised in the EU in 2013 as a 3 + 1 schedule for infants, with three doses administered during the first year of life and a booster dose at 12 months.4 In 2015, the UK was the first country to implement a routine infant 4CMenB immunisation programme. However, cost-effectiveness and epidemiological considerations led the UK to choose a novel 2 + 1 schedule with doses at 2, 4, and 12 months of age, despite an absence of corresponding immunogenicity data.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
